How Argenica’s ARG-007 Passed a Critical FDA Test with Tenecteplase

middle.news 8:26am on Thursday 4th of December, 2025 AEDT • Healthcare Read Story

How Argenica’s ARG-007 Passed a Critical FDA Test with Tenecteplase

8:26am on Thursday 4th of December, 2025 AEDT Key Points ARG-007 shows no inhibition of tenecteplase’s clot-dissolving activity Study addresses FDA clinical hold on Argenica’s IND application Complements prior positive results with alteplase interaction study Two remaining FDA-requested assays underway, data expected Q1 2026 Read Story

middle. Tap to Read Tap the card to read the full analysis about Argenica Therapeutics (ASX:AGN) OPEN ARTICLE